 |
|
|
|
 |
|
|
 Contact |  Print version |  PDF version |  Recommend company
|
Medawar Centre, Robert Robinson Avenue, The Oxford Science Park
OX4 4GA Oxford
United Kingdom
|
|
Portrait
Oxford BioMedica is a biopharmaceutical company specializing in cancer immunotherapy and gene-based therapies. The Company was established in 1995, as a spin-out from Oxford University, and is listed on the London Stock Exchange. The Company has a platform of gene delivery technologies, which are based on highly engineered viral systems. Its lead product candidate is TroVax(R), an immunotherapy for multiple solid cancers, which is licensed to sanofi-aventis for global development and commercialization. TroVax is in Phase III development. Oxford BioMedica has three other products in clinical development, including ProSavin(R), a novel gene-based treatment for Parkinson's disease, in a Phase I/II trial. The Company is underpinned by over 80 patent families, which represent one of the broadest patent estates in the field.
Industrial Sectors
Additional information
Oxford BioMedica plc
Oxford, United Kingdom
News
|
|
|
|
|
|
Top
